Exclusive: Gsk Eyes Replacing Human Genome Board

NEW YORK/LONDON (Reuters) - GlaxoSmithKline Plc plans to launch a campaign to replace the entire board of Human Genome Sciences Inc with its own nominees, stepping up its $2.6 billion hostile bid for the U.S. biotech company, sources familiar with the situation said on Wednesday.

Sections:  business   
RELATED ARTICLES
  • Bayer to pay $1.1B for California firm Conceptus
    Germany drug company Bayer AG says it intends to buy California-based Conceptus to expand its birth control offerings. Bayer said Monday it would launch a pupublicblic offer to pay $31.00 per share for all the stock in Conceptus, Inc. That means Bayer would pay $1.1 billion. More
  • As drug industry’s influence over research grows, so does the potential for bias
    For drugmaker GlaxoSmithKline, the 17-page article in the New England Journal of Medicine represented a coup. The 2006 report described a trial that compared three diabetes drugs and concluded that Avandia, the company’s new drug, performed best. More
  • Drug Makers Stalled in a Cycle of Quality Lapses and Shortages
    ...These recent quality lapses at big drug companies show that contamination and shoddy practices extend well beyond the loosely regulated compounding pharmacies that have attracted attention because of their link to an outbreak of meningitis... [S]everal industry observers and former plant employees said that the recent quality issues were troubling and that manufacturers had been reluctant to fix problems because stopping production was simply too costly in a business where profits were driven by volume. More
  • Exclusive: GSK set for Human Genome takeover
    GlaxoSmithKline is expected to announce a deal to buy Human Genome Sciences for about $2.8 billion as soon as Monday, ending a three-month hostile pursuit of the U.S. biotech company on friendly terms after sweetening its offer. More
  • GlaxoSmithKline to pay $3B for health fraud
    British drugmaker GlaxoSmithKline will pay $3 billion in fines - the largest health care fraud settlement in U.S. history - for criminal and civil violations involving 10 drugs that are taken by millions of people. The Justice Department said Monday that GlaxoSmithKline PLC will plead guilty to promoting popular antidepressants Paxil and Wellbutrin for unapproved uses. More

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News